IRIS
PALUMBO, Giuseppe Alberto Maria
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.940
EU - Europa 3.799
AS - Asia 2.648
SA - Sud America 409
AF - Africa 374
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 7
Totale 15.189
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.707
SG - Singapore 1.577
IT - Italia 1.358
IE - Irlanda 990
CN - Cina 859
UA - Ucraina 583
BR - Brasile 373
CI - Costa d'Avorio 253
CA - Canada 218
RU - Federazione Russa 215
DE - Germania 150
SE - Svezia 122
SN - Senegal 75
FI - Finlandia 52
BE - Belgio 51
VN - Vietnam 51
GB - Regno Unito 50
FR - Francia 47
CH - Svizzera 39
NL - Olanda 34
IN - India 30
CZ - Repubblica Ceca 24
NG - Nigeria 20
AT - Austria 19
ES - Italia 17
GR - Grecia 17
JP - Giappone 16
UZ - Uzbekistan 15
AR - Argentina 12
HK - Hong Kong 12
LB - Libano 12
AU - Australia 11
PK - Pakistan 10
PL - Polonia 10
CO - Colombia 9
MA - Marocco 9
MX - Messico 9
TR - Turchia 9
IR - Iran 8
KR - Corea 8
BD - Bangladesh 7
EU - Europa 7
IQ - Iraq 6
KE - Kenya 6
BG - Bulgaria 5
EG - Egitto 5
IL - Israele 5
JO - Giordania 5
ZA - Sudafrica 5
AE - Emirati Arabi Uniti 4
RO - Romania 4
AZ - Azerbaigian 3
EC - Ecuador 3
HN - Honduras 3
NO - Norvegia 3
PY - Paraguay 3
VE - Venezuela 3
AM - Armenia 2
BO - Bolivia 2
CL - Cile 2
MY - Malesia 2
PS - Palestinian Territory 2
AL - Albania 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
GE - Georgia 1
GY - Guiana 1
HR - Croazia 1
JM - Giamaica 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LT - Lituania 1
LU - Lussemburgo 1
MD - Moldavia 1
NZ - Nuova Zelanda 1
PE - Perù 1
PH - Filippine 1
PT - Portogallo 1
SC - Seychelles 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
TH - Thailandia 1
Totale 15.189
Salva come PNG Salva come JPEG
Città #
Santa Clara 1.479
Dublin 966
Chandler 964
Singapore 917
Houston 778
Jacksonville 567
Chicago 536
Boardman 398
Catania 318
Ashburn 289
Lawrence 257
Cambridge 254
Abidjan 253
Andover 250
Nanjing 220
Toronto 157
Des Moines 135
Civitanova Marche 134
Wilmington 110
San Mateo 97
Rome 82
Nanchang 76
Dakar 75
Shenyang 61
Saint Petersburg 60
Hebei 58
Milan 58
Florence 57
Jiaxing 53
Ottawa 51
Brussels 48
Grafing 47
Changsha 41
Dong Ket 40
Hefei 40
Washington 39
Los Angeles 35
Palermo 35
Munich 34
Tianjin 34
Beijing 32
Falls Church 29
Helsinki 29
Council Bluffs 27
Messina 27
São Paulo 27
Seattle 26
The Dalles 26
Lappeenranta 23
Moscow 21
Abuja 20
Bronte 18
Den Haag 18
Bremen 17
Brno 16
Jinan 14
Naples 14
Turin 14
Ann Arbor 13
Maracena 12
Pune 12
Amsterdam 11
Augusta 11
Belo Horizonte 11
Guangzhou 11
Hanoi 11
Hong Kong 11
Kunming 11
Misterbianco 11
Norwalk 10
Paris 10
Aci Sant'Antonio 9
Hangzhou 9
Campinas 8
Curitiba 8
Fukuoka 8
Genoa 8
Hanover 8
Redwood City 8
Rio de Janeiro 8
Seoul 8
Tokyo 8
Ardabil 7
Bari 7
Bernareggio 7
Cassano delle Murge 7
Frankfurt Am Main 7
Mascalucia 7
New York 7
Shanghai 7
Vittoria 7
Zhengzhou 7
Aachen 6
Aci Catena 6
Porto Alegre 6
Amman 5
Brasília 5
Frankfurt am Main 5
Goiânia 5
Liberty Lake 5
Totale 10.849
Salva come PNG Salva come JPEG
Nome #
Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy 231
Patient-reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromes 211
Mutation and haplotype studies of familial Mediterranean fever reveal new ancestral relationships and evidence for a high carrier frequency with reduced penetrance in the Ashkenazi Jewish population 190
Baseline factors associated with response to ruxolitinib: An independent study on 408 patients with myelofibrosis 165
Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: The FIL FOLL05 trial 151
CXCL12/CXCR4 axis supports mitochondrial trafficking in tumor myeloma microenvironment 124
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 116
Inhibition of TLR4 signaling affects mitochondrial fitness and overcomes bortezomib resistance in myeloma plasma cells 110
Focus on Osteosclerotic Progression in Primary Myelofibrosis 98
IGFBP-6 Alters Mesenchymal Stromal Cell Phenotype Driving Dasatinib Resistance in Chronic Myeloid Leukemia 97
Ixazomib improves bone remodeling and counteracts sonic hedgehog signaling inhibition mediated by myeloma cells 93
In vitro apoptotic response of freshly isolated chronic myeloid leukemia cells to all-trans retinoic acid and cytosine arabinoside 90
Terapia del mieloma multiplo 89
Pegylated asparaginase-induced liver injury, a case-based review and data from pharmacovigilance 88
Immune off-target effects of Brentuximab Vedotin in relapsed/refractory Hodgkin Lymphoma 86
13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia 84
Monocytic myeloid-derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib 84
A cytoprotective role for the heme oxygenase-1/CO pathway during neural differentiation of human mesenchymal stem cells 82
A MULTICENTRIC STUDY TO EVALUATE THE EFFICACY OF EPOIETIN ZETA (BIOSIMILAR OF EPO ALPHA) IN LOW RISK MYELODISPLASTIC PATIENTS 81
TLR4 signaling drives mesenchymal stromal cells commitment to promote tumor microenvironment transformation in multiple myeloma 81
Iron regulates myeloma cell/macrophage interaction and drives resistance to bortezomib 81
A physiological role for the neuropeptide luteinizing hormone-releasing hormone (LHRH) during the maturation of thymus Gland function 79
In-vitro NET-osis induced by COVID-19 sera is associated to severe clinical course in not vaccinated patients and immune-dysregulation in breakthrough infection 79
Mesenchymal stromal cells in tumor microenvironment remodeling of BCR-ABL negative myeloproliferative diseases 78
ACVR1: A Novel Therapeutic Target to Treat Anemia in Myelofibrosis 78
Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53 78
SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation 77
PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy 76
Angiogenic factors (VEGF, bFGF, and HGF) in multiple myeloma: higher levels in bone marrow than in peripheral blood 74
Alternation of epirubicin and mitoxantrone in CHOP-like regimens retains efficacy and reduces overall toxicity in elderly patients with high and intermediate grade non-Hodgkin lymphomas 74
Effects of second-generation tyrosine kinase inhibitors towards osteogenic differentiation of human mesenchymal cells of healthy donors 74
The Apoptotic Machinery As A Biological Complex System: Analysis Of Its Omics And Evolution, Identification Of Candidate Genes For Fourteen Major Types Of Cancer And Experimental Validation in CML And Neuroblastoma 74
The apoptotic machinery as a biological complex system: analysis of its omics and evolution, identification of candidate genes for fourteen major types of cancer, and experimental validation in CML and neuroblastoma 74
Plasticity of High-Density Neutrophils in Multiple Myeloma is Associated with Increased Autophagy via STAT3 74
High-density neutrophils in MGUS and multiple myeloma are dysfunctional and immune-suppressive due to increased STAT3 downstream signaling 74
Pyrrolidinedithiocarbamate induces apoptosis in human acute myelogenous leukemic cells affecting NF-kappaB activity 73
The Apoptotic Machinery As A Biological Complex System: Analysis Of Its Omics And Evolution, Identification Of Candidate Genes For Fourteen Major Types Of Cancer And Experimental Validation in CML And Neuroblastoma 73
ITF2357 Interferes with apoptosis and inflammatory pathways in the HL-60 model: A gene expression study 73
Prognostic value of CD34+ peak in peripheral blood during mobilization in intermediate-risk AML patients treated in first CR by autologous or allogeneic transplantation 73
Correction: TLR4 signaling drives mesenchymal stromal cells commitment to promote tumor microenvironment transformation in multiple myeloma (Cell Death & Disease, (2019), 10, 10, (704), 10.1038/s41419-019-1959-5) 73
Broad copy neutral-loss of heterozygosity regions and rare recurring copy number abnormalities in normal karyotype-acute myeloid leukemia genomes 72
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial 72
Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI) 72
Hedgehog signaling pathways in multiple myeloma 71
Effects of imatinib mesylate in osteoblastogenesis 70
PREDICTORS FOR RESPONSE TO RUXOLITINIB IN REAL-LIFE: AN OBSERVATIONAL INDEPENDENT STUDY ON 266 PATIENTS WITH MYELOFIBROSIS 70
Angiogenesis in acute myeloid leukemia 69
HIGH-RESOLUTION SNP ARRAYS AS AN ADDITIONAL TOOL TO SEARCH FOR GENETIC DEFECTS INVOLVED IN PROGRESSION FROM MYELODYSPLASTIC SINDROME TO ACUTE LEUKEMIA 69
BORTEZOMIB INHIBITS OSTEOCLASTOGENESIS AND MODULATE CHIT1 AND YKL40 EXPRESSION 69
Infection control in patients with myelodysplastic syndromes who are candidates for active treatment: Expert panel consensus-based recommendations 69
Arsenic trioxide and ascorbic acid interfere with the BCL2 family genes in patients with myelodysplastic syndromes: An ex-vivo study 69
The Apoptotic Machinery As A Biological Complex System: Analysis of its Omics, Identification of Candidate Genes for Fourteen Major Types of Cancer and Experimental Validation in CML and Neuroblastoma 68
Hypoxia Induces Imatinib Resistance in CML Cell Lines 68
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study 68
Antitumor activity of bortezomib alone and in combination with TRAIL in human acute myeloid leukemia 67
Emangioma, plasmocitoma e mieloma multiplo del rachide 67
Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes 67
Mesenchymal Stem Cells (MSC) Regulate Activation of Granulocyte-Like Myeloid Derived Suppressor Cells (G-MDSC) in Chronic Myeloid Leukemia Patients 66
In vitro sensitivity of B-CLL cells to Fludarabine and Interferons 66
Different in vitro alemtuzumab induced apoptosis on T and B lymphocytes of B-CLL patients 66
IMATINIB INCREASES CYTOTOXICITY OF MELPHALAN AND DECREASES PROLONGATION OF G2-M PHASE IN HUMAN K562 CELLS 66
Antitumor Activity of Bortezomib Alone and in Combination with TRAIL in Human Acute Myeloid Leukemia 66
Off-Label Use of Venetoclax in Patients With Acute Myeloid Leukemia: Single Center Experience and Data From Pharmacovigilance Database 66
Peripheral blood stem cell contamination evaluated by a highly sensitive molecular method fails to predict outcome of autotransplanted multiple myeloma patients 65
Multidrug resistance mechanisms in chronic lymphocytic leukaemia 65
Targeted Metabolomics Highlights Dramatic Antioxidant Depletion, Increased Oxidative/Nitrosative Stress and Altered Purine and Pyrimidine Concentrations in Serum of Primary Myelofibrosis Patients 64
Peptidergic modulation of immune system development: role of luteinizing hormone-releasing hormone. 64
Absolute Count of Myeloid Derived Suppressor Cells (MDSC) Is Able to Predict the Response to Early-PET In Hodgkin Lymphoma 64
ANTITUMOR ACTIVITY OF BORTEZOMIB ALONE AND IN COMBINATION WITH TRAIL IN HUMAN ACUTE MYELOID LEUKEMIA C.M.S 64
BROAD COPY NEUTRAL-LOSS OF HETEROZYGOSITY REGIONS AND RARE RECURRING COPY NUMBER ABNORMALITIES IN KARYOTYPICALLY NORMAL ACUTE MYELOID LEUKEMIA GENOMES 64
Evaluation of taxol cytotoxicity on B-CLL cells in vitro 64
Bortezomib Could Reduce Cell Viability by Activation of Heme Oxygenase 1 in Multiple Myeloma Cells 63
The NLR and LMR ratio in newly diagnosed MM patients treated upfront with novel agents 63
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients 63
13q14 Chromosome Deletion Size and Number of Deleted Cells Influence Prognosis In Chronic Lymphocytic Leukemia 63
IMPACT OF EPOETIN ZETA (BIOSIMILAR EPO alpha) IN LOW-RISK MDS: ITT ANALYSIS OF A MULTICENTRIC PHASE 2 STUDY 62
Cross-talk communication in the neuroendocrine-reproductive-immune axis. Age-dependent alterations in the common communication networks. 62
A good response rate to recombinant erythropoietin alone may be expected in selected myelodysplastic patients. A preliminary clinical study 62
Il mitoxantrone in polichemioterapia associato allo schema CVP nel trat- tamento dei linfomi non hodgkin. 62
Additional Genetic Alterations and Clonal Evolution of MPNs with Double Mutations on the MPL Gene: Two Case Reports 61
Is endoscopic ultrasound clinically useful for follow-up of gastric lymphoma? 61
Effects of micronised microencapsulated ferric pyrophosphate supplementation in patients with advanced cancer and iron deficiency: A single-centre cohort pilot study 61
Enhanced Antitumor Activity by the Combination of Dasatinib and Selinexor in Chronic Myeloid Leukemia 60
Clinical outcome of SARS-CoV-2 infections occurring in multiple myeloma patients after vaccination and prophylaxis with tixagevimab/cilgavimab 60
BROAD COPY NEUTRAL-LOSS OF HETEROZYGOSITY REGIONS AND RARE RECURRING COPY NUMBER ABNORMALITIES IN KARYOTYPICALLY NORMAL ACUTE MYELOID LEUKEMIA GENOMES 59
Effects of proton irradiations on functional characteristics of bone marrow mesenchimal stem cells 59
HISTONE DEACETYLASE INHIBITOR ITF2357 EXERT SIGNIFICANT ANTI-PROLIFERATIVE AND PRO-APOPTOTIC EFFECTS ON THE P39 CELL LINE: A GENE EXPRESSION STUDY 59
BRIT1/MCPH1 expression in chronic myeloid leukemia and its regulation of the G2/M checkpoint. 59
Proteomic analysis reveals autophagy as pro-survival pathway elicited by long-term exposure with 5-azacitidine in high-risk myelodysplasia 59
MONOCYTIC MYELOID DERIVED SUPPRESSOR CELLS (M-MDSC) AS PROGNOSTIC FACTOR IN DASATINIB TREATED PATIENTS WITH CHRONIC MYELOID LEUKEMIA 59
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients 59
Target Therapy for Extramedullary Relapse of FLT3-ITD Acute Myeloid Leukemia: Emerging Data from the Field 58
Monocytic Myeloid Derived Suppressor CELLS (M-MDSC) As Prognostic Factor in Chronic Myeloid Leukemia Patients Treated with Dasatinib 58
Elevated vascular endothelial growth factor (VEGF) serum levels in idiopathic myelofibrosis 58
Lactate trafficking inhibition restores sensitivity to proteasome inhibitors and orchestrates immuno-microenvironment in multiple myeloma 57
Saprochete capitata: Emerging Infections from Uncommon Microorganisms in Hematological Diseases 57
GRANULOCYTE-LIKE MYELOID DERIVED SUPPRESSOR CELLS ARE INCREASED IN MULTIPLE MYELOMA DUE TO IMMUNOLOGICAL DYSREGULATION OF MESENCHYMAL STEM CELLS 57
Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: An Italian MYNERVA Project 56
Nuclear translocation of Heme oxygenase-1 confers resistance to imatinib in chronic myeloid leukemia cells 56
Low serum levels of vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in IFN-treated chronic myeloid leukemia (CML) patients 56
Totale 7.676
Salva come PNG Salva come JPEG
Categoria #
all - tutte 64.158
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 64.158
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020182 0 0 0 0 0 0 0 0 0 0 122 60
2020/20211.162 20 92 115 49 383 16 124 13 139 12 119 80
2021/20221.861 159 255 2 13 373 38 280 78 167 32 35 429
2022/20233.157 292 156 73 221 257 536 28 541 768 60 155 70
2023/20241.839 112 251 93 131 87 345 97 139 10 51 324 199
2024/20255.346 57 977 356 317 1.366 644 226 236 455 625 87 0
Totale 15.709